Who are Fluval AB vaccination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): FluarixTM, TIV, Vaxigrip®, Trivalent sub-unit influenza vaccine, trivalent seasonal influenza vaccine, High-Dose Quadrivalent Influenza Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fluval-ab-vaccination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Fluval AB vaccination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fluval AB vaccination (Fluval AB vaccination) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology / Infectious Disease.

marketed Inactivated influenza vaccine Immunology / Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Fluval AB vaccination (Fluval AB vaccination) — Fluart Innovative Vaccine Ltd, Hungary. Fluval AB is an inactivated influenza A and B vaccine that stimulates the immune system to produce antibodies against seasonal influenza viruses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Fluval AB vaccination TARGET	Fluval AB vaccination	Fluart Innovative Vaccine Ltd, Hungary	marketed	Inactivated influenza vaccine
FluarixTM	FluarixTM	GlaxoSmithKline	marketed	inactivated influenza vaccine
TIV	TIV	Folia Biotech Inc.	marketed	Inactivated influenza vaccine
Vaxigrip®	Vaxigrip®	National University Hospital, Singapore	marketed	Inactivated influenza vaccine
Trivalent sub-unit influenza vaccine	Trivalent sub-unit influenza vaccine	University of Witwatersrand, South Africa	marketed	inactivated influenza vaccine
trivalent seasonal influenza vaccine	trivalent seasonal influenza vaccine	Sinovac Biotech Co., Ltd	marketed	inactivated influenza vaccine
High-Dose Quadrivalent Influenza Vaccine	High-Dose Quadrivalent Influenza Vaccine	Tor Biering-Sørensen	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

GlaxoSmithKline · 16 drugs in this class
Seqirus · 5 drugs in this class
Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
Green Cross Corporation · 4 drugs in this class
Novartis · 2 drugs in this class
SK Chemicals Co., Ltd. · 2 drugs in this class
Sanofi · 2 drugs in this class
Hospital Israelita Albert Einstein · 2 drugs in this class
McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
Il-Yang Pharm. Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fluval AB vaccination — Competitive Intelligence Brief. https://druglandscape.com/ci/fluval-ab-vaccination. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing